Blockade of the expression of sensitization and tolerance by ondansetron, a 5-HT3 receptor antagonist, administered during withdrawal from intermittent and continuous cocaine.
The present experiment evaluated the ability of the 5-HT3 antagonist, ondansetron, administered during withdrawal from chronic cocaine administration, to block the expression of sensitization and tolerance induced by the intermittent or continuous administration of cocaine, respectively. Rats were pretreated with 40 mg/kg/per day cocaine for 14 days by either s.c. injections or osmotic minipumps, or 0.9% saline, administered via osmotic minipump. During the first 5 days of withdrawal from this pretreatment regimen, all rats received a daily s.c. injection of 0-1.0 mg/kg ondansetron. On day seven of withdrawal from the cocaine pretreatment (2 days after the final ondansetron injection) all subjects received a 15.0 mg/kg i.p. cocaine challenge. Their behavior was then rated according to the Ellinwood and Balster (1974) scale for 60 min. The results indicated that daily injections of ondansetron, on days 1-5 of withdrawal from the pretreatment regimen, had no significant effect on the subsequent behavioral response to cocaine in the saline control subjects. In contrast, daily injections of ondansetron, on days 1-5 of withdrawal from intermittent cocaine administration, significantly blocked the expression of sensitization. In the continuous cocaine group, ondansetron injections, on days 1-5 of withdrawal from continuous cocaine administration, also blocked the expression of behavioral tolerance. The results therefore indicate that changes in 5-HT3 receptor function are associated with the expression of tolerance and sensitization, respectively.
King
G R
GR
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA. george@psych.duke.edu
Xiong
Z
Z
Ellinwood
E H
EH
D000818:Animals; D003042:Cocaine / Q000009:adverse effects*; D004361:Drug Tolerance; D008297:Male; D008960:Models, Psychological; D009294:Narcotics / Q000009:adverse effects*; D017294:Ondansetron / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology
D009294:Narcotics; D012702:Serotonin Antagonists; D017294:Ondansetron; D003042:Cocaine